Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Upgraded by StockNews.com

Abeona Therapeutics (NASDAQ:ABEO) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Wednesday.

A number of other equities analysts have also recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $18.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, October 29th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research report on Thursday, October 31st.

Abeona Therapeutics Stock Performance

Shares of ABEO opened at $5.82 on Wednesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. Abeona Therapeutics has a 1 year low of $3.05 and a 1 year high of $9.01. The stock has a market capitalization of $252.78 million, a P/E ratio of -2.16 and a beta of 1.52. The company’s fifty day moving average is $6.19 and its two-hundred day moving average is $5.27.

Institutional Trading of Abeona Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Rosalind Advisors Inc. increased its stake in shares of Abeona Therapeutics by 4.7% in the third quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock worth $11,578,000 after buying an additional 82,000 shares during the last quarter. Western Standard LLC increased its stake in shares of Abeona Therapeutics by 7.0% in the third quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock worth $10,732,000 after buying an additional 110,998 shares during the last quarter. Citigroup Inc. increased its stake in shares of Abeona Therapeutics by 10.1% in the third quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock worth $3,897,000 after buying an additional 56,332 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Abeona Therapeutics by 581.6% in the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock worth $2,134,000 after buying an additional 429,456 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Abeona Therapeutics by 21.7% in the third quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock worth $2,942,000 after buying an additional 83,050 shares during the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.